Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hMSCs in Anthracycline-Associated Cardiomyopathy
NCT02962661Phase 1Suspended
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2020
- Primary completion
- Jul 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of allogeneic human mesenchymal stem cells in cardiomyopathy and heart failure (HF) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events at 6 months and Change in left ventricular ejection fraction at 6 months. Started Jul 2020; status: suspended.
02
Drugs
allogeneic human mesenchymal stem cells
03
Conditions
cardiomyopathyheart failure (HF)
Beyond the preview
Go deeper on NCT02962661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02962661.